2025-12-19 - Analysis Report
Here's a comprehensive analysis of Tempus AI Inc. (TEM) based on the provided data, broken down into simple numbers followed by analysis:

**1. Return Rate Comparison:**

*   **TEM Cumulative Return:** 11.05%
*   **S&P 500 (VOO) Cumulative Return:** 28.31%
*   **Divergence:** -17.26% (TEM underperformed VOO)
*   **Relative Divergence:** 28.8 (TEM is near the lower end of its divergence range).

**Analysis:**

*   Tempus AI has significantly underperformed the S&P 500 over the period.
*   The relative divergence suggests that the underperformance is closer to the minimum observed in the dataset's history.

**Company Overview (from provided data):** Not provided.

**Alpha, Beta Analysis:**

|            | CAGR    | MDD     | Alpha   | Beta  | Cap(B) |
| ---------- | ------- | ------- | ------- | ----- | ------ |
| 2023-2025  | 11.0%   | 76.7%   | -16.0%  | 0.3   | 11.1   |

*   **CAGR (Compound Annual Growth Rate):** 11.0%
*   **MDD (Maximum Drawdown):** 76.7%
*   **Alpha:** -16.0%
*   **Beta:** 0.3
*   **Cap(B):** 11.1

**Analysis:**

*   The stock has an 11% CAGR from 2023-2025, but with an alarmingly high Maximum Drawdown (MDD) of 76.7%, indicating substantial risk.
*   The negative alpha of -16.0% suggests the stock has underperformed its benchmark (risk-adjusted).
*   A Beta of 0.3 indicates that TEM is less volatile than the market (S&P 500).
*   The market cap is $11.1B.

**2. Recent Stock Price Fluctuations:**

*   **Current Close:** $62.21
*   **Previous Close:** $64.62
*   **Change:** -$2.41 (-3.72%)
*   **5-day SMA:** $66.84
*   **20-day SMA:** $72.93
*   **60-day SMA:** $80.34

**Analysis:**

*   The stock price is trending downwards, currently below all three Simple Moving Averages (SMAs).
*   The negative change of -3.72% indicates a recent significant drop in price.

**3. Index Indicators:**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment)
*   **RSI (Relative Strength Index):** 12.66 (Oversold)
*   **PPO (Percentage Price Oscillator):** -1.42
*   **Hybrid Signal:** Cash 0% / Buy 100% (14 shares - Very Safe - MRI: 0.90) Monthly Invest 5% of total investment ($1,000) (Cash Ratio: 0% on 2025-12-01)
*   **Recent Divergence Change (20 days):** -11.0 (Negative - Short-term decline)
*   **Expected Return:** NaN (Not Available)

**Analysis:**

*   The MRI suggests a "Medium Investment" recommendation, but the low RSI (12.66) indicates the stock may be oversold and potentially due for a rebound.
*   The PPO being negative suggests a downward trend.
*   The recent negative divergence change confirms short-term downward momentum.
*   The Hybrid Signal indicates a 100% buy signal with monthly investment based on a more conservative MRI score.

**4. Recent News & Significant Events:**

*   **[2025-12-18]** Executive Sells Shares: EVP Erik Phelps sold 1,302 shares.
*   **[2025-12-18]** Bullish Article: "Tempus AI: A Healthcare Hyper-Growth Opportunity For The Risk Tolerant" (Seeking Alpha).
*   **[2025-11-25]** FDA Clearance/Earnings Discussion: Stock opinions on FDA clearance and earnings.
*   **[2025-11-24]** Stock Comparison: TEM vs. BFLY comparison for upside potential.
*   **[2025-12-02]** FDA Clearance Impact: Discussion of how FDA clearance might affect investment.
*   **[2025-12-18]** Top Healthcare Stocks: Listed as a top healthcare stock for the quarter.

**Analysis:**

*   The news presents a mixed picture. An executive selling shares could be interpreted negatively, but inclusion in "Top Healthcare Stocks" and articles highlighting "Hyper-Growth Opportunity" are positive. The discussion around FDA clearance and its impact is a key factor influencing investor sentiment.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (2.14 on a 1-5 scale)
*   **Number of Opinions:** 12
*   **Target Price:** $90.17 (Average), $105 (High), $80 (Low)

**Analysis:**

*   Analysts, on average, have a "Buy" rating for the stock and see significant upside potential from the current price. The average target price is much higher than the current trading price.

**5. Comprehensive Analysis & Summary:**

*   **Overall Assessment:** Tempus AI presents a high-risk, high-reward investment opportunity.

*   **Key Positives:**
    *   Strong analyst consensus ("Buy" rating) with a significantly higher average target price.
    *   Potential hyper-growth opportunity in the healthcare sector (as highlighted in some news articles).
    *   Recent FDA clearance can be a significant catalyst.

*   **Key Negatives:**
    *   Significant underperformance compared to the S&P 500.
    *   Very high Maximum Drawdown (MDD) indicates extreme price volatility.
    *   Negative Alpha suggests poor risk-adjusted returns.
    *   Recent executive share sale could be a concerning signal.
    *   Downward price trend, RSI indicating oversold conditions.

*   **Investment Recommendation:** Due to the high MDD and overall risk profile, investment in Tempus AI is suitable only for investors with a high-risk tolerance. While analyst ratings suggest upside, the stock's performance and volatility warrant caution. Further due diligence is recommended, particularly regarding the impact of FDA clearance and future earnings reports. The recent executive share sale warrants further investigation. The RSI suggests a potential for a short-term rebound, but the overall trend is currently downward. The hybrid signal indicates that this may be a good time to buy, but consider the mixed information.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.